NCT06784726
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +20 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Clinical trial condition
Refractory High Grade B-Cell Lymphoma
Explore clinical trials studying Refractory High Grade B-Cell Lymphoma. Study availability and eligibility vary by location and protocol.
10 public trials
5 recruiting studies
Refractory High Grade B-Cell Lymphoma trial results
NCT05672251
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +20 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
Recruiting
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
NCT05077527
- Conditions
- AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, Blood-Borne Infections, +36 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- University of Illinois at Chicago Chicago, Illinois, United States
- Memorial Sloan Kettering Cancer Center New York, United States
- Montefiore Medical Center - Moses Campus The Bronx, New York, United States
NCT06271057
- Conditions
- Diffuse Large B-cell Lymphoma Refractory, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal Large B-Cell Lymphoma, +1 more
- Locations
-
- Hopital Henri Mondor Créteil, France
- Chu Dijon Bourgogne Dijon, France
- Chu de Grenoble La Tronche, France
- Chru de Lille Lille, France
NCT05418088
- Conditions
- Burkitt Lymphoma, Chronic Disease, DNA Virus Infections, +44 more
- Locations
-
- Nationwide Children's Hospital Columbus, Ohio, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Active, not recruiting
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
NCT05025800
- Conditions
- Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, +31 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, not recruiting
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT05507541
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +36 more
- Locations
-
- University of Iowa Iowa City, Iowa, United States
- Mayo Clinic Rochester, Minnesota, United States
NCT04432506
- Conditions
- Hematologic Diseases, Hematologic Neoplasms, Hematopoietic and Lymphoid Cell Neoplasm, +20 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
NCT03309878
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +14 more
- Locations
-
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States
- Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
NCT04409314
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +33 more
- Locations
-
- University of California, San Francisco San Francisco, California, United States